03) and 0% showed virological

recurrence verus 8/21 (38%) not co-infected (p=0.01). Other possible predictors of recurrence (previous therapies for HCV, patients, grafts and donors conditions at LT, time of HCV-RNA undetectability…) did not show any significance. Nevertheless, at logistic regression the only parameter significantly associated with lower histological recurrence rate was pre-LT HCV-RNA undetectability > 6 months (p=0.02), irrespective of previous therapies for HCV. Graft was lost in 9/50 (18%) patients: graft survival was 86% at 1 year from LT, 81% at 2, 5 and 10 years. 4/50 (8%) patients died: survival was 96% at 1 year from LT, 91% at 2, 5 and 10 years. No significant predictors of mortality and lost of graft were found among HCV-related variables. CONCLUSIONS: In patients with HCV-related liver disease and undetectable HCV-RNA Y-27632 order at LT the HCV recurrence rates are far lower than those observed in HCV-RNA positive patients. The only variable strongly associated with lower HCV recurrence rate seems to be a pre-LT period of HCV-RNA undetectability > 6 months, irrespective of previous therapies for HCV. In our cohort, grafts and patients survival rates after LT are comparable to those observed in patients without an history of HCV infection, and no HCV-re-lated

variable affect these rates. A curious issue is the hypothetical “protective Ibrutinib solubility dmso role” from HCV recurrence that some data suggest for HBV-HCV co-infection. Disclosures: The following people have nothing to disclose: Alessandro Risso, MCE公司 Francesco Tandoi, Silvia Martini, Renato Romagnoli, Mauro Salizzoni Introduction: Treatment of the hepatitis

C virus (HCV) post-liver transplantation has been notoriously difficult. In this population, drug-drug interactions often have serious consequences and immunosuppressant therapy may make viral eradication more difficult. The interferon-free regimen used in the COSMOS study combined two Direct Acting Antivirals (DAAs), sofosbuvir and simeprevir. Early data suggests that it appears safe and effective in non-cirrhotic and cirrhotic individuals. Little data is available on the safety and efficacy of this treatment in patients post-liver transplant. Here we describe our experience using sofosbuvir and simeprevir in patients after liver transplant. Methods: This was an IRB approved retrospective analysis. Thirty-two patients who underwent liver transplantation were started on a 12-week course of sofosbuvir and simeprevir. Two patients were also given ribavirin. Basic laboratory data, viral kinetics, side effects, and changes in immune suppression were recorded. Only patients infected with GT 1a (55%) or 1b (45%) were included. SVR 12 data will be available at time of presentation. Statistics performed using JMP SAS with non-parametric, parametric or multivariate analysis as deemed necessary.